The discovery of soluble GC (sGC) stimulators and sGC activators provided valuable tools to
elucidate NO–sGC signalling and opened novel pharmacological opportunities for …

The nitric oxide (NO)–soluble guanylate cyclase (sGC)–cyclic guanosine monophosphate
(cGMP) pathway plays a key role in the pathogenesis of pulmonary hypertension (PH) …

EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional
cohort study in patients with pulmonary hypertension treated with riociguat. Patients were …

Background Pulmonary hypertension is a common and serious complication of chronic
obstructive pulmonary disease (COPD). Studies suggest that cigarette smoke can initiate …

Interdisciplinary research at the interface of chemistry, physiology, and biomedicine have
uncovered pivotal roles of nitric oxide (NO) as a signaling molecule that regulates vascular …

Nitric oxide (NO)-stimulated cyclic guanosine monophosphate (cGMP) is a key regulator of
cardiovascular health, as NO-cGMP signalling is impaired in diseases like pulmonary …

Chronic thromboembolic pulmonary hypertension (CTEPH), defined as precapillary
pulmonary hypertension (PH) by right heart catheterization and imaging consistent with …

Balloon pulmonary angioplasty (BPA) has recently been elevated as a class I
recommendation for the treatment of inoperable or residual chronic thromboembolic …

Pulmonary arterial hypertension (PAH) is a progressive disease. Although great progress
has been made in its diagnosis and treatment in recent years, its mortality rate is still very …

Objective The soluble guanylate cyclase stimulator riociguat is approved for the treatment of
adult patients with pulmonary arterial hypertension (PAH) and inoperable or …